ArticleCancer chemotherapy and pharmacology2025

A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors.

Susan C Scott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.